CDT
Conduit Pharmaceuticals Inc
$
2.170
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.250
Open
2.200
VWAP
2.18
Vol
97.36K
Mkt Cap
5.22M
Low
2.120
Amount
212.67K
EV/EBITDA(TTM)
--
Total Shares
73.83M
EV
5.73M
EV/OCF(TTM)
--
P/S(TTM)
--
Conduit Pharmaceuticals, Inc. is a multi-asset clinical-stage, life science company. The Company facilitates the development and commercialization of clinical assets. The Company acquires and funds the development of Phase 2-ready assets, builds an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeks exit through third-party license deals following successful clinical trials. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), AZD5658 (Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), for the treatment, prevention, and prophylaxis of idiopathic male infertility.
Show More
Valuation Metrics
The current forward P/E ratio for Conduit Pharmaceuticals Inc (CDT.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Conduit Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+35.67%
-4.01M
Operating Profit
FY2025Q1
YoY :
+44.88%
-5.15M
Net Income after Tax
FY2025Q1
YoY :
-72.48%
-19.86
EPS - Diluted
FY2025Q1
YoY :
+83.84%
-4.33M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 366.37% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
691.1K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 366.37% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
691.1K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CDT News & Events
Events Timeline
2025-07-08 (ET)
2025-07-08
08:39:39
Conduit Pharmaceuticals to explore cryptocurrency reserve strategy
2025-07-07 (ET)
2025-07-07
08:34:15
Conduit Pharmaceuticals files four new patent applications
2025-06-04 (ET)
2025-06-04
08:32:02
Conduit Pharmaceuticals enters joint development agreement with Manoira
Sign Up For More Events
Sign Up For More Events
News
4.5
07-08NewsfilterConduit Engages Consultant to Explore Cryptocurrency Reserve Strategy
3.5
07-07NewsfilterConduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
7.5
06-04NewsfilterConduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Sign Up For More News
People Also Watch
AWH
Aspira Women's Health Inc
0
USD
-14.63%
NURO
NeuroMetrix Inc
0
USD
+4.80%
HIHO
Highway Holdings Ltd
1.630
USD
-1.21%
HOFV
Hall of Fame Resort & Entertainment Co
0
USD
-5.70%
GRNQ
GreenPro Capital Corp
2.120
USD
-1.40%
ZCMD
Zhongchao Inc
1.040
USD
-0.95%
BFRI
Biofrontera Inc
1.080
USD
+19.87%
APM
Aptorum Group Ltd
1.930
USD
+19.81%
POLA
Polar Power Inc
2.090
USD
-4.57%
GV
Visionary Holdings Inc
1.520
USD
-7.88%
FAQ
What is Conduit Pharmaceuticals Inc (CDT) stock price today?
The current price of CDT is 2.17 USD — it has increased 0.46 % in the last trading day.
What is Conduit Pharmaceuticals Inc (CDT)'s business?
What is the price predicton of CDT Stock?
What is Conduit Pharmaceuticals Inc (CDT)'s revenue for the last quarter?
What is Conduit Pharmaceuticals Inc (CDT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Conduit Pharmaceuticals Inc (CDT)'s fundamentals?
How many employees does Conduit Pharmaceuticals Inc (CDT). have?